Plandai Biotechnology Expanding Footprint of Phytofare into U.S. with Continued Sales

/EINPresswire.com/ -- NEW YORK, NY--(Marketwired - May 04, 2017) - Plandaí Biotechnology (OTCQB: PLPL) announced last week that its highly bioavailable Phytofare^® Catechin Complex would be the active ingredient in Capital Brand's reformulated and soon-to-be released SuperFood Fat Burning Boost^®, which is used with the well-known brand NutriBullet. This week we learned that thanks to a deal with Coyne Healthcare -- Plandaí's signature brand Phytofare^® will make its way to the U.S. and Europe as the star ingredient in Coyne Healthcare's product Origine 8^™.

Coyne Healthcare placed an order for 1.2 million of Plandaí's Origine 8^™ capsules, which is a product that not only uses the highly bioavailable green tea extract, Phytofare^® Catechin Complex, but further enhances the bioavailability of the extract by using an advanced liposome technology developed and clinically validated to improve the delivery of nutritional substances.

Origine 8^™ is a product that entraps all 8 of the catechins of the tea plant, and according to Plandaí, it is the only catechin-based capsule on the market backed by human clinical studies that prove it has superior bioavailability.

Coyne Healthcare has already been selling Plandaí's unique product in South Africa, but it now expects to launch Origine 8^™ this month in both the U.S. and Europe. The good news for Plandaí is that Coyne Healthcare has forecasted sales of 10.6 million Origine 8^™ capsules in 2017, and Coyne expects sales to further increase to 24 million Origine 8^™ capsules in 2018.

Coyne makes its products (http://coynehealthcare.co.za/#products) available through pharmacies, health food stores and medical practitioners, so for both NutriBullet and Coyne Healthcare to bring Plandaí's signature brand to the U.S., investors will have a great opportunity to physically see their investment up close and personal.

Sales at Plandaí and the recognition that the company is gaining globally, is clearly a response to the efforts made by the new COO, Callum Cottrell-Duffield, well before now. He led the company's sales and marketing team in its effort to grow the brand and expand the company's footprint worldwide after Plandaí's signature product was available for mass production and ready to market on a much broader scale last year. His work to increase sales and marketing throughout Africa, the United States, Europe, Asia and South America by telling the Plandaí story, is starting to pay off now in 2017.

And, with brands like NutriBullet and Coyne Healthcare, who both use and market only the highest quality ingredients in their products, advertising the Phytofare^® name, it shouldn't take long for Plandaí to grow quite an impressive sales footprint worldwide.

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles.

We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $5,000 per month by Plandai Biotechnology for content development. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information: www.stockmarketmediagroup.com.